Camber Launches Eletriptan Hydrobromide Tablets
Camber Pharmaceuticals continues to strengthen its range of treatment options with the introduction of Eletriptan Hydrobromide Tablets [EL-e-TRIP-tan].
Eletriptan Hydrobromide Tablets are indicated for the acute treatment of migraine, with or without aura in adults.
Eletriptan Hydrobromide Tablets are available in:
|
Strength |
Size |
| 20 mg |
6 (1 x 6) Unit-dose Tablets |
| 40 mg |
6 (1 x 6) Unit-dose Tablets |
To learn more about this product, visit: www.camberpharma.com/eletriptan-hydrobromide
Recent articles
- Camber Awarded 2025 Supplier of the Year by OptiSource
- Camber Launches Eletriptan Hydrobromide Tablets
- Camber Launches Abacavir and Lamivudine Tablets, USP
- Camber’s Parent Company, Hetero, Partners with the Gates Foundation to Supply Generic Lenacapavir for HIV Prevention
- Camber Adds 800 mg Darunavir Tablets to Product Family
- Camber Expands Portfolio with 10 New Generic Drug Launches in Q3 2025





